Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.53 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.36 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.34 |
| ▸ | LPL | P06858 | 3/20 | 0.32 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.32 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17904530 | 0.84 | FFAR1 (0.57) | FFAR1DGAT1AAK1LPLLIPG | |
| SCHEMBL14746347 | 0.83 | FFAR1 (0.56) | FFAR1DGAT1AAK1LPLLIPG | |
| SCHEMBL13412137 | 0.83 | FFAR1 (0.59) | FFAR1DGAT1AAK1KDM5BLPL | |
| SCHEMBL21794845 | 0.82 | FFAR1 (0.47) | FFAR1DGAT1AAK1 | |
| SCHEMBL2588010 | 0.81 | FFAR1 (0.59) | FFAR1DGAT1AAK1LPLLIPG | |
| SCHEMBL23022205 | 0.80 | FFAR1 (0.52) | FFAR1DGAT1AAK1LPLLIPG | |
| SCHEMBL34468062 | 0.79 | FFAR1 (0.57) | FFAR1DGAT1AAK1LPLLIPG | |
| SCHEMBL18614513 | 0.79 | FFAR1 (0.46) | FFAR1DGAT1AAK1 | |
| SCHEMBL19861553 | 0.78 | FFAR1 (0.56) | FFAR1DGAT1AAK1LPLLIPG | |
| SCHEMBL29584057 | 0.77 | FFAR1 (0.52) | FFAR1DGAT1LPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024253416-A1 | PYRIMIDINE/PYRIDINE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORPORATION (KR) | 2024-12-12 | — | — | WO | disclosed |
| EP-4352059-A1 | TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS | Incyte Corporation (US) | 2024-04-17 | — | — | EP | disclosed |
| WO-2022261160-A1 | TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION (US) | 2022-12-15 | — | — | WO | disclosed |